Cited by 709interferon and immune responsesCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

An orally available non-nucleotide STING agonist with antitumor activity

Pan, Bo-Sheng, Perera, Samanthi A., Piesvaux, Jennifer A., Presland, Jeremy P., Schroeder, Gottfried K., Cumming, Jared N., Trotter, B. Wesley, Altman, Michael D., Buevich, Alexei V., Cash, Brandon, Cemerski, Saso, Chang, Wonsuk, Chen, Yiping, Dandliker, Peter J., Feng, Guo, Haidle, Andrew, Henderson, Timothy, Jewell, James, Kariv, Ilona, Knemeyer, Ian, Kopinja, Johnny, Lacey, Brian M., Laskey, Jason, Lesburg, Charles A., Liang, Rui, Long, Brian J., Lu, Min, Ma, Yanhong, Minnihan, Ellen C., O’Donnell, Greg, Otte, Ryan, Price, Laura, Rakhilina, Larissa, Sauvagnat, Berengere, Sharma, Sharad, Tyagarajan, Sriram, Woo, Hyun, Wyss, Daniel F., Xu, Serena, Bennett, David Jonathan, Addona, George H.·2020·Science

DOI 10.1126/science.aba6098

Open this paper in CoChat — free account

Abstract

Targeting STING for cancer therapy: Activation of the STING (stimulator of interferon genes) protein by cyclic dinucleotide metabolites plays a critical role in antitumor immunity. The development of synthetic STING agonists is therefore being pursued as a strategy for cancer therapy, but the inherent instability of dinucleotides has limited current efforts. Pan et al. and Chin et al. identified stable STING agonists that act in a “closed” conformation similar to the natural STING ligand, cyclic guanosine monophosphate–adenosine monophosphate (see the Perspective by Gajewski and Higgs). The small molecules can be given orally—an advantage over previously developed STING agonists, which required intratumoral administration. After oral or systemic administration in mice, the agonists activated STING and diverse immune cell types to promote antitumor immunity. These studies represent progress toward clinically viable STING agonists for cancer immunotherapy. Science , this issue p. eaba6098 , p. 993 ; see also p. 921

Integrity signals

Registry

Crossref · 10.1126/science.aba6098

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
MOLREP : an Automated Program for Molecular Replacement
Vagin, A. A., & Teplyakov, A. (1997) · Journal of Applied Crystallography · doi:10.1107/s0021889897006766 · Cited by 4,756
MolProbity: all-atom contacts and structure validation for proteins and nucleic acids
Davis, I., Leaver‐Fay, A., Chen, V. B., Block, J. N., Kapral, G. J., Wang, X., Murray, L. W., Arendall, W. B., Snoeyink, J. S., Richardson, J. S., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm216 · Cited by 3,918
Dysregulated pH: a perfect storm for cancer progression
Webb, B. A., Chimenti, M. S., Jacobson, M. P., & Barber, D. L. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3110 · Cited by 2,279
Data processing and analysis with the autoPROC toolbox
Vonrhein, C., Flensburg, C., Keller, P., Sharff, A., Smart, O. S., Paciorek, W. A., Womack, T. O., & Bricogne, G. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911007773 · Cited by 2,084
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity
Corrales, L., Glickman, L. H., McWhirter, S. M., Kanne, D. B., Sivick, K. E., Katibah, G. E., Woo, S.-R., Lemmens, E., Banda, T., Leong, J. J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.031 · Cited by 1,560
Acidity Generated by the Tumor Microenvironment Drives Local Invasion
Estrella, V. C., Chen, T., Lloyd, M. C., Wojtkowiak, J. W., Cornnell, H. H., Ibrahim‐Hashim, A., Bailey, K. M., Balagurunathan, Y., Rothberg, J. M., Sloane, B. F., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2796 · Cited by 1,404
Cyclic GMP-AMP Containing Mixed Phosphodiester Linkages Is An Endogenous High-Affinity Ligand for STING
Zhang, X., Shi, H., Wu, J., Zhang, X., Sun, L., Chen, C., & Chen, Z. J. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.05.022 · Cited by 1,118

Flagged first, then by citations

Show all 36 references

Sorted by citations

Macrophages as tools and targets in cancer therapy
Mantovani, A., Allavena, P., Marchesi, F., & Garlanda, C. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00520-5 · Cited by 1,807
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
Turning cold tumors into hot tumors by improving T-cell infiltration
Liu, Y., & Sun, Z. (2021) · Theranostics · doi:10.7150/thno.58390 · Cited by 867
Amplifying STING activation by cyclic dinucleotide–manganese particles for local and systemic cancer metalloimmunotherapy
Sun, X., Zhang, Y., Li, J., Park, K. S., Han, K., Zhou, X., Xu, Y., Nam, J., Xu, J., Shi, X., et al. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00962-9 · Cited by 808
The cGAS–STING pathway and cancer
Samson, N., & Ablasser, A. (2022) · Nature Cancer · doi:10.1038/s43018-022-00468-w · Cited by 740
Roles of natural killer cells in immunity to cancer, and applications to immunotherapy
Wolf, N. K., Kissiov, D. U., & Raulet, D. H. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00732-1 · Cited by 622
Turning cold tumors hot: from molecular mechanisms to clinical applications
Zhang, J., Huang, D., Saw, P. E., & Song, E. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.04.010 · Cited by 534
Targeting cytokine and chemokine signaling pathways for cancer therapy
Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 528
Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Meric-Bernstam, F., Sweis, R. F., Hodi, F. S., Messersmith, W. A., Andtbacka, R. H. I., Ingham, M., Lewis, N., Chen, X., Pelletier, M., Chen, X., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1963 · Cited by 418
STING Agonists as Cancer Therapeutics
Amouzegar, A., Chelvanambi, M., Filderman, J. N., Storkus, W. J., & Luke, J. J. (2021) · Cancers · doi:10.3390/cancers13112695 · Cited by 419
Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy
Garland, K. M., Sheehy, T. L., & Wilson, J. T. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00750 · Cited by 372
STING-induced regulatory B cells compromise NK function in cancer immunity
Li, S., Mirlekar, B., Johnson, B. M., Brickey, W. J., Wrobel, J. A., Yang, N., Song, D., Entwistle, S., Tan, X. M., Deng, M., et al. (2022) · Nature · doi:10.1038/s41586-022-05254-3 · Cited by 359
STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity
Dane, E. L., Belessiotis‐Richards, A., Backlund, C. M., Wang, J., Hidaka, K., Milling, L. E., Bhagchandani, S. H., Melo, M. B., Wu, S., Li, N., et al. (2022) · Nature Materials · doi:10.1038/s41563-022-01251-z · Cited by 342
Biomolecular Condensates and Cancer
Boija, A., Klein, I. A., & Young, R. A. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.003 · Cited by 338
Therapeutic targeting of tumour myeloid cells
Barry, S. T., Gabrilovich, D. I., Sansom, O. J., Campbell, A. D., & Morton, J. P. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00546-2 · Cited by 305
STING inhibitors target the cyclic dinucleotide binding pocket
Hong, Z., Mei, J., Li, C., Bai, G., Maimaiti, M., Hu, H., Yu, W., Sun, L., Zhang, L., Cheng, D., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2105465118 · Cited by 296
Regulation of cGAS–STING signalling and its diversity of cellular outcomes
Zhang, Z., & Zhang, C. (2025) · Nature Reviews Immunology · doi:10.1038/s41577-024-01112-7 · Cited by 287
STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer
Wang, Q., Bergholz, J. S., Ding, L., Lin, Z., Kabraji, S. K., Hughes, M. E., He, X., Xie, S., Jiang, T., Wang, W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30568-1 · Cited by 275
Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy
Aval, L. M., Pease, J. E., Sharma, R., & Pinato, D. J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103323 · Cited by 253
The STING1 network regulates autophagy and cell death
Zhang, R., Kang, R., & Tang, D. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00613-4 · Cited by 266
Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study
Meric‐Bernstam, F., Sweis, R. F., Kasper, S., Hamid, O., Bhatia, S., Dummer, R., Stradella, A., Long, G. V., Spreafico, A., Shimizu, T., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2235 · Cited by 281
Interferon-dependent SLC14A1+ cancer-associated fibroblasts promote cancer stemness via WNT5A in bladder cancer
Ma, Z., Li, X., Mao, Y., Chen, W., Huang, Z., Li, G., Yin, J., Liang, X., & Liu, Z. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.11.005 · Cited by 256
STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma
Hu, J. Y., Rivera, F. J. S., Wang, Z., Johnson, G. N., Ho, Y.-J., Ganesh, K., Umeda, S., Gan, S., Mujal, A. M., Delconte, R. B., et al. (2023) · Nature · doi:10.1038/s41586-023-05880-5 · Cited by 261
ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation
Hu, M., Zhou, M., Bao, X., Pan, D., Jiao, M., Liu, X., Li, F., & Li, C. (2020) · Journal of Clinical Investigation · doi:10.1172/jci139333 · Cited by 260
Mitochondrial DNA-triggered innate immune response: mechanisms and diseases
Hu, M.-M., & Shu, H. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01086-x · Cited by 263
Exploiting innate immunity for cancer immunotherapy
Yi, M., Li, T., Niu, M., Mei, Q., Zhao, B., Chu, Q., Dai, Z., & Wu, K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01885-w · Cited by 250
Zinc cyclic di-AMP nanoparticles target and suppress tumours via endothelial STING activation and tumour-associated macrophage reinvigoration
Yang, K., Han, W., Jiang, X., Piffkó, A., Bugno, J., Han, C., Li, S., Liang, H. L., Xu, Z., Zheng, W., et al. (2022) · Nature Nanotechnology · doi:10.1038/s41565-022-01225-x · Cited by 224
Multifaceted functions of STING in human health and disease: from molecular mechanism to targeted strategy
Zhang, Z., Zhou, H., Ouyang, X., Dong, Y., Sarapultsev, A., Luo, S., & Hu, D. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01252-z · Cited by 222
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Pharmacological activation of STING blocks SARS-CoV-2 infection
Li, M., Ferretti, M., Ying, B., Descamps, H. C., Lee, E. M., Dittmar, M., Lee, J. S., Whig, K., Kamalia, B., Dohnalová, L., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abi9007 · Cited by 188
Self-citation
The cGAS‒STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications
Shen, M., Jiang, X., Qiu, P., Oyang, L., Ren, Z., Wang, J., Peng, M., Zhou, Y., Deng, X., & Liao, Q. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01691-5 · Cited by 210
Delivery of STING agonists for adjuvanting subunit vaccines
Herck, S. V., Feng, B., & Tang, L. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114020 · Cited by 182
Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01363-8 · Cited by 184
Activating cGAS-STING pathway with ROS-responsive nanoparticles delivering a hybrid prodrug for enhanced chemo-immunotherapy
Cao, L., Tian, H., Fang, M., Xu, Z., Tang, D., Chen, J., Yin, J., Xiao, H., Shang, K., Han, H., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121856 · Cited by 179
Targeting STING to promote antitumor immunity
Chin, E. N., Sulpizio, A., & Lairson, L. L. (2022) · Trends in Cell Biology · doi:10.1016/j.tcb.2022.06.010 · Cited by 170
Chemically programmed STING-activating nano-liposomal vesicles improve anticancer immunity
Chen, X., Meng, F., Xu, Y., Li, T., Chen, X., & Wang, H. (2023) · Nature Communications · doi:10.1038/s41467-023-40312-y · Cited by 173
The balance of STING signaling orchestrates immunity in cancer
Lanng, K. R. B., Lauridsen, E. L., & Jakobsen, M. R. (2024) · Nature Immunology · doi:10.1038/s41590-024-01872-3 · Cited by 179
Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers
Yi, M., Niu, M., Zhang, J., Li, S., Zhu, S., Yan, Y., Li, N., Zhou, P., Chu, Q., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01155-6 · Cited by 163
Clathrin-associated AP-1 controls termination of STING signalling
Liu, Y., Xu, P., Rivara, S., Liu, C., Ricci, J., Ren, X., Hurley, J. H., & Ablasser, A. (2022) · Nature · doi:10.1038/s41586-022-05354-0 · Cited by 166
Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer
Chang, W., Altman, M. D., Lesburg, C. A., Perera, S. A., Piesvaux, J., Schroeder, G. K., Wyss, D. F., Čemerski, S., Chen, Y., DiNunzio, E., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02197 · Cited by 165
Self-citation
Nanobiomaterial-based vaccination immunotherapy of cancer
Chen, F., Wang, Y., Gao, J., Saeed, M., Li, T., Wang, W., & Yu, H. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120709 · Cited by 159
Leveraging NKG2D Ligands in Immuno-Oncology
Fuertes, M. B., Domaica, C. I., & Zwirner, N. W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.713158 · Cited by 152
Maintaining manganese in tumor to activate cGAS-STING pathway evokes a robust abscopal anti-tumor effect
Wang, C., Sun, Z., Zhao, C., Zhang, Z., Wang, H., Liu, Y., Guo, Y., Zhang, B., Gu, L., Yu, Y., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.01.036 · Cited by 145
A kinase-cGAS cascade to synthesize a therapeutic STING activator
McIntosh, J. A., Liu, Z., Andresen, B. M., Marzijarani, N. S., Moore, J. C., Marshall, N., Borra‐Garske, M., Obligacion, J. V., Fier, P. S., Peng, F., et al. (2022) · Nature · doi:10.1038/s41586-022-04422-9 · Cited by 142
Self-citation
Targeted Degradation of PD‐L1 and Activation of the STING Pathway by Carbon‐Dot‐Based PROTACs for Cancer Immunotherapy
Su, W., Tan, M., Wang, Z., Zhang, J., Huang, W., Song, H., Wang, X., Ran, H., Gao, Y., Nie, G., et al. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202218128 · Cited by 138
The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy
Hines, J. B., Kacew, A. J., & Sweis, R. F. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01361-0 · Cited by 133
Demystifying the cGAS-STING pathway: precision regulation in the tumor immune microenvironment
Wang, Q., Yu, Y., Zhuang, J., Liu, R., & Sun, C. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02380-0 · Cited by 152
Current understanding of the cGAS-STING signaling pathway: Structure, regulatory mechanisms, and related diseases
Pan, J., 宁波大学农产品质量安全危害因子与风险防控国家重点实验室, 浙. 宁. 3., Fei, C.-J., Hu, Y., Wu, X., Nie, L., Chen, J., 宁波大学梅山校区海洋学院生物化学与分子生物学实验室, 浙. 宁. 3., & 浙江省海洋生物工程重点实验室, 浙. 宁. 3. (2023) · 动物学研究 · doi:10.24272/j.issn.2095-8137.2022.464 · Cited by 138
Medicinal plant-derived mtDNA via nanovesicles induces the cGAS-STING pathway to remold tumor-associated macrophages for tumor regression
Liu, J., Xiang, J., Jin, C., Ye, L., Wang, L., Gao, Y., Lv, N., Zhang, J., You, F., Qiao, H., et al. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01835-0 · Cited by 132
Acid‐Ionizable Iron Nanoadjuvant Augments STING Activation for Personalized Vaccination Immunotherapy of Cancer
Chen, F., Li, T., Zhang, H., Saeed, M., Liu, X., Huang, L., Wang, X., Gao, J., Hou, B., Lai, Y., et al. (2022) · Advanced Materials · doi:10.1002/adma.202209910 · Cited by 125
Biochemistry, Cell Biology, and Pathophysiology of the Innate Immune cGAS–cGAMP–STING Pathway
Ritchie, C., Carozza, J. A., & Li, L. (2022) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-040320-101629 · Cited by 123
Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors
Ouyang, P., Wang, L., Wu, J., Tian, Y., Chen, C., Li, D., Yao, Z., Chen, R., Xiang, G., Gong, J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1344272 · Cited by 123
The complementarity of DDR, nucleic acids and anti-tumour immunity
Kornepati, A. V. R., Rogers, C. M., Sung, P., & Curiel, T. J. (2023) · Nature · doi:10.1038/s41586-023-06069-6 · Cited by 117
Small molecule-based immunomodulators for cancer therapy
Wu, Y., Yang, Z., Cheng, K., Bi, H., & Chen, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.11.007 · Cited by 114
Simultaneous Activation of Pyroptosis and cGAS‐STING Pathway with Epigenetic/ Photodynamic Nanotheranostic for Enhanced Tumor Photoimmunotherapy
Ding, F., Liu, J., Ai, K., Xu, C., Mao, X., Liu, Z., & Xiao, H. (2023) · Advanced Materials · doi:10.1002/adma.202306419 · Cited by 114
Targeted delivery of a STING agonist to brain tumors using bioengineered protein nanoparticles for enhanced immunotherapy
Wang, B., Tang, M., Yuan, Z., Li, Z., Hu, B., Bai, X., Chu, J., Xu, X., & Zhang, X.-Q. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.02.026 · Cited by 112
Multifunctional Mesoporous Polydopamine‐Based Systematic Delivery of STING Agonist for Enhanced Synergistic Photothermal‐Immunotherapy
Zeng, W., Li, Z., Huang, Q., Ding, C., Li, Y., Wang, W., Shi, Z., Yang, Y., Chen, H., Mei, L., et al. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202307241 · Cited by 111
MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer
Kitajima, S., Tani, T., Springer, B. F., Campisi, M., Osaki, T., Haratani, K., Chen, M., Knelson, E. H., Mahadevan, N. R., Ritter, J., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.08.015 · Cited by 107
cGAS-STING pathway mediates activation of dendritic cell sensing of immunogenic tumors
Li, G., Zhao, X., Zheng, Z., Zhang, H., Wu, Y., Shen, Y., & Chen, Q. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05191-6 · Cited by 114
Engineered Nanovaccine Targeting Clec9a+ Dendritic Cells Remarkably Enhances the Cancer Immunotherapy Effects of STING Agonist
Gou, S., Liu, W., Wang, S., Chen, G., Chen, Z., Qiu, L., Zhou, X., Wu, Y., Qi, Y., & Gao, Y. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c03243 · Cited by 107
Tetrahedral DNA Nanostructure with Interferon Stimulatory DNA Delivers Highly Potent Toxins and Activates the cGAS‐STING Pathway for Robust Chemotherapy and Immunotherapy
Zhang, L., Wang, Y., Karges, J., Tang, D., Zhang, H., Zou, K., Song, J., & Xiao, H. (2022) · Advanced Materials · doi:10.1002/adma.202210267 · Cited by 99
STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer
Ding, L., Wang, Q., Martincuks, A., Kearns, M. J., Jiang, T., Lin, Z., Cheng, X., Qian, C., Xie, S., Kim, H., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005627 · Cited by 98
Sono‐Driven STING Activation using Semiconducting Polymeric Nanoagonists for Precision Sono‐Immunotherapy of Head and Neck Squamous Cell Carcinoma
Jiang, J., Zhang, M., Lyu, T., Chen, L., Wu, M., Li, R., Li, H., Wang, X., Jiang, X., & Xu, Z. C. (2023) · Advanced Materials · doi:10.1002/adma.202300854 · Cited by 98
Pyridinium Rotor Strategy toward a Robust Photothermal Agent for STING Activation and Multimodal Image-Guided Immunotherapy for Triple-Negative Breast Cancer
Ning, S., Shangguan, P., Zhu, X., Ou, X., Wang, K., Suo, M., Shen, H., Lu, X., Wei, X., Zhang, T., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c15534 · Cited by 101
Turning cold tumors into hot tumors to ignite immunotherapy
Liu, Y., Wang, Y., Wang, S., Li, J., He, W. A., Fan, X.-J., & Wan, X. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02477-6 · Cited by 124
The mechanism of STING autoinhibition and activation
Liu, S., Yang, B., Hou, Y., Cui, K., Yang, X., Li, X., Chen, L., Liu, S., Zhang, Z., Jia, Y., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.03.029 · Cited by 102
Mechanistic Rationales Guiding Combination Hepatocellular Carcinoma Therapies Involving Immune Checkpoint Inhibitors
Cheu, J. W., & Wong, C. C. (2021) · Hepatology · doi:10.1002/hep.31840 · Cited by 91
Universal STING mimic boosts antitumour immunity via preferential activation of tumour control signalling pathways
Wang, Y., Li, S., Hu, M., Yang, Y., McCabe, E., Zhang, L., Withrow, A. M., Ting, J. P. ‐., & Liu, R. (2024) · Nature Nanotechnology · doi:10.1038/s41565-024-01624-2 · Cited by 99
Polymeric STING Pro‐agonists for Tumor‐Specific Sonodynamic Immunotherapy
Yu, J., He, S., Zhang, C., Xu, C., Huang, J., Xu, M., & Pu, K. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202307272 · Cited by 93
Lanthanide-Nucleotide Coordination Nanoparticles for STING Activation
Luo, Z., Liang, X., He, T., Qin, X., Li, X., Li, Y., Li, L., Loh, X. J., Gong, C., & Liu, X. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c03266 · Cited by 87
PRMT1 mediated methylation of cGAS suppresses anti-tumor immunity
Liu, J., Bu, X., Chu, C., Dai, X., Asara, J. M., Siciński, P., Freeman, G. J., & Wei, W. (2023) · Nature Communications · doi:10.1038/s41467-023-38443-3 · Cited by 89
STING Agonist-Derived LNP-mRNA Vaccine Enhances Protective Immunity Against SARS-CoV-2
Zhang, Y., Yan, J., Hou, X., Wang, C., Kang, D. D., Xue, Y., Du, S., Deng, B., McComb, D. W., Liu, S., et al. (2023) · Nano Letters · doi:10.1021/acs.nanolett.2c04883 · Cited by 88
Overcoming challenges in the delivery of STING agonists for cancer immunotherapy: A comprehensive review of strategies and future perspectives
Huang, C., Shao, N., Huang, Y., Chen, J., Wang, D., Hu, G., Zhang, H., Luo, L., & Xiao, Z. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100839 · Cited by 88
Gasdermin-E-mediated pyroptosis drives immune checkpoint inhibitor-associated myocarditis via cGAS-STING activation
Sun, S.-J., Jiao, X., Chen, Z., Cao, Q., Zhu, J., Shen, Q., Liu, Y. F., Zhang, Z., Xu, F., Shi, Y. L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50996-5 · Cited by 93
Immunostimulatory Polymers as Adjuvants, Immunotherapies, and Delivery Systems
Weiss, A. M., Hossainy, S., Rowan, S. J., Hubbell, J. A., & Esser-Kahn, A. P. (2022) · Macromolecules · doi:10.1021/acs.macromol.2c00854 · Cited by 89
cGAS-STING signaling in the tumor microenvironment
Liu, Z., Wang, D., Zhang, J., Xiang, P., Zeng, Z., Xiong, W., & Shi, L. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216409 · Cited by 87
cGAS‐STING pathway agonists are promising vaccine adjuvants
Tian, X., Ai, J., Tian, X., & Wei, X. (2024) · Medicinal Research Reviews · doi:10.1002/med.22016 · Cited by 86
Nanodelivery of cGAS-STING activators for tumor immunotherapy
Guo, J., & Huang, L. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.08.006 · Cited by 84
STING, a promising target for small molecular immune modulator: A review
Liu, Y., Lü, X., Qin, N., Qiao, Y., Xing, S., Liu, W., Feng, F., Liu, Z., & Sun, H. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113113 · Cited by 80
Nanomedicines harnessing cGAS-STING pathway: sparking immune revitalization to transform ‘cold’ tumors into ‘hot’ tumors
Ying, X., Chen, Q., Yang, Y., Wu, Z., Zeng, W., Miao, C., Huang, Q., & Ai, K. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02186-6 · Cited by 87
Therapeutic strategies to remodel immunologically cold tumors
Wang, M., Wang, S., Desai, J., Trapani, J. A., & Neeson, P. J. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1226 · Cited by 79
Non-canonical STING–PERK pathway dependent epigenetic regulation of vascular endothelial dysfunction via integrating IRF3 and NF-κB in inflammatory response
Li, X., Chen, X., Zheng, L., Chen, M., Zhang, Y., Zhu, R., Chen, J., Gu, J., Yin, Q., Jiang, H., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.08.015 · Cited by 76
cGAS–STING, an important signaling pathway in diseases and their therapy
Li, Q., Wu, P., Du, Q., Hanif, U., Hu, H., & Li, K. (2024) · MedComm · doi:10.1002/mco2.511 · Cited by 83
Mitochondrion‐Targeted Type I Photodynamic Therapy for Agonist Independent cGAS‐STING Activation
Xu, Y., An, D., Zhang, T., Wu, X., Wang, S., Shao, J., Qu, L., Guo, Y., & Dong, X. (2025) · Advanced Materials · doi:10.1002/adma.202418894 · Cited by 73
A Manganese Phosphate Nanocluster Activates the cGAS‐STING Pathway for Enhanced Cancer Immunotherapy
Gao, M., Xie, Y., Lei, K., Zhao, Y., Kurum, A., Herck, S. V., Guo, Y., Hu, X., & Tang, L. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100065 · Cited by 73
Activation of the cGAS-STING pathway combined with CRISPR-Cas9 gene editing triggering long-term immunotherapy
Lu, Q., Chen, R., Du, S., Chen, C., Pan, Y., Luan, X., Yang, J., Zeng, F., He, B., Han, X., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121871 · Cited by 74
cGAMP-activated cGAS–STING signaling: its bacterial origins and evolutionary adaptation by metazoans
Patel, D. J., Yu, Y., & Xie, W. (2023) · Nature Structural & Molecular Biology · doi:10.1038/s41594-023-00933-9 · Cited by 79
Agonists and Inhibitors of the cGAS-STING Pathway
Yu, X., Cai, L., Yao, J., Li, C., & Wang, X. (2024) · Molecules · doi:10.3390/molecules29133121 · Cited by 76
Manganese-coordinated nanoparticle with high drug-loading capacity and synergistic photo-/immuno-therapy for cancer treatments
Chen, H., Qu, H., Pan, Y., Cheng, W., & Xue, X. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122745 · Cited by 71
Potentiating cancer immunotherapies with modular albumin-hitchhiking nanobody–STING agonist conjugates
Kimmel, B. R., Arora, K., Chada, N. C., Bharti, V., Kwiatkowski, A. J., Finkelstein, J. E., Hanna, A., Arner, E. N., Sheehy, T. L., Pastora, L. E., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01400-0 · Cited by 74
Immunotherapy with a sting
Gajewski, T. F., & Higgs, E. F. (2020) · Science · doi:10.1126/science.abc6622 · Cited by 68
The Evolution of STING Signaling and Its Involvement in Cancer
Vashi, N., & Bakhoum, S. F. W. (2021) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.12.010 · Cited by 72
Cholesterol-binding motifs in STING that control endoplasmic reticulum retention mediate anti-tumoral activity of cholesterol-lowering compounds
Zhang, B., Laursen, M. F., Hu, L., Hazrati, H., Narita, R., Jensen, L. S., Hansen, A. S., Huang, J., Zhang, Y., Ding, X., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47046-5 · Cited by 73
Activation of Stimulation of Interferon Genes (STING) Signal and Cancer Immunotherapy
Luo, K.-W., Li, N., Ye, W., Gao, H., Luo, X., & Cheng, B. (2022) · Molecules · doi:10.3390/molecules27144638 · Cited by 68
Self-Assembled STING-Activating Coordination Nanoparticles for Cancer Immunotherapy and Vaccine Applications
Sun, X., Huang, X., Park, K. S., Zhou, X., Kennedy, A. A., Pretto, C. D., Wu, Q., Wan, Z., Xu, Y., Gong, W., et al. (2024) · ACS Nano · doi:10.1021/acsnano.3c11374 · Cited by 70
STING Suppresses Mitochondrial VDAC2 to Govern RCC Growth Independent of Innate Immunity
Zhu, Z., Zhou, X., Du, H., Cloer, E. W., Zhang, J., Liu, M., Wang, Y., Tan, X. M., Hepperla, A. J., Simon, J. M., et al. (2022) · Advanced Science · doi:10.1002/advs.202203718 · Cited by 71
Lipid‐based nanoparticles as drug delivery systems for cancer immunotherapy
Hao, Y., Ji, Z., Zhou, H., Wu, D., Gu, Z., Wang, D., & ten Dijke, P. (2023) · MedComm · doi:10.1002/mco2.339 · Cited by 71
Small-molecule agents for cancer immunotherapy
Wang, F., Fu, K., Wang, Y., Pan, C., Wang, X., Liu, Z., Yang, C., Zheng, Y. Y., Li, X., Lu, Y., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.12.010 · Cited by 71
Systemic nano-delivery of low-dose STING agonist targeted to CD103+ dendritic cells for cancer immunotherapy
Doshi, A. S., Cantin, S., Prickett, L. B., Mele, D. A., & Amiji, M. M. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.054 · Cited by 64
Combining cisplatin and a STING agonist into one molecule for metalloimmunotherapy of cancer
Zhang, S., Song, D., Yu, W., Li, J., Wang, X., Li, Y., Zhao, Z., Xue, Q., Zhao, J., Li, J., et al. (2023) · National Science Review · doi:10.1093/nsr/nwae020 · Cited by 65

Authors: Pan, B.-S., Perera, S. A., Piesvaux, J. A., Presland, J. P., Schroeder, G. K., Cumming, J. N., Trotter, B. W., Altman, M. D., Buevich, A. V., Cash, B., Cemerski, S., Chang, W., Chen, Y., Dandliker, P. J., Feng, G., Haidle, A., Henderson, T., Jewell, J., Kariv, I., Knemeyer, I., Kopinja, J., Lacey, B. M., Laskey, J., Lesburg, C. A., Liang, R., Long, B. J., Lu, M., Ma, Y., Minnihan, E. C., O’Donnell, G., Otte, R., Price, L., Rakhilina, L., Sauvagnat, B., Sharma, S., Tyagarajan, S., Woo, H., Wyss, D. F., Xu, S., Bennett, D. J., & Addona, G. H.
Affiliations: Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Department of Discovery Oncology, Merck & Co., Inc., Kenilworth, NJ, USA.
Department of Quantitative Biosciences, Merck & Co., Inc., Kenilworth, NJ, USA.
Corresponding author: Pan, Bo-Sheng
Perera, Samanthi A.
Piesvaux, Jennifer A.
Presland, Jeremy P.
Schroeder, Gottfried K.
Cumming, Jared N.
Trotter, B. Wesley
Bennett, David Jonathan
Addona, George H.
ORCID: Pan, Bo-Sheng
Perera, Samanthi A.
Piesvaux, Jennifer A.
Presland, Jeremy P.
Schroeder, Gottfried K.
Cumming, Jared N.
Trotter, B. Wesley
Buevich, Alexei V.
Cash, Brandon
Cemerski, Saso
Chang, Wonsuk
Chen, Yiping
Dandliker, Peter J.
Feng, Guo
Haidle, Andrew
Kariv, Ilona
Knemeyer, Ian
Kopinja, Johnny
Lacey, Brian M.
Laskey, Jason
Lesburg, Charles A.
Liang, Rui
Long, Brian J.
Lu, Min
Minnihan, Ellen C.
O’Donnell, Greg
Otte, Ryan
Price, Laura
Rakhilina, Larissa
Sauvagnat, Berengere
Sharma, Sharad
Tyagarajan, Sriram
Woo, Hyun
Wyss, Daniel F.
Bennett, David Jonathan
Addona, George H.
Venue: Science
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2020-08-21
Volume: 369
Issue: 6506
ISSN: 0036-8075 (ISSN-L)
1095-9203
DOI: 10.1126/science.aba6098
OpenAlex: W3061136593
Cited by: 694
References: 36
Citations by year: 2026: 127 · 2025: 159 · 2024: 124 · 2023: 107 · 2022: 102 · 2021: 61 · 2020: 14
FWCI: 25.83
Type: journal article
Language: en
Open access: closed
Locations: Science (publishedVersion)
PubMed (publishedVersion)
DORA PSI (Paul Scherrer Institute) (submittedVersion)
Topics: Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: STING agonist, MSA-2, oral drug delivery, innate immunity, antitumor immunity, interferon-beta, anti-PD-1 combination therapy, covalent dimers, tumor microenvironment acidification, cancer immunotherapy
MeSH terms: STING Protein, Administration, Oral, Animals, Antineoplastic Agents, Humans, Membrane Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

An orally available non-nucleotide STING agonist with antitumor activity

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks